Domestic growth trajectory in key areas to remain strong for Torrent Pharma

More gains for the stock will depend on the recovery in the US market

With a growth of 19 per cent YoY in November, generic pharma major Torrent Pharmaceuticals (Torrent) continues to outperform peers. The growth was aided by higher sales of vitamins, pain medications and gastrointestinal drugs, helping it beat the average growth in the Indian pharma market (IPM) of 6.6 per cent. The domestic market accounts for half of Torrent’s consolidated sales.

While Shelcal (calcium, vitamins) and extensions remains its single largest brand with annual sales of Rs 400 crore, pain medication (Chymoral Forte) and Nexpro RD used in treating acid reflux are the other top selling brands which posted robust growth